First Header Logo Second Header Logo

Connection

Anthony Atala to Urinary Bladder Neoplasms

Back to Details
This is a "connection" page, showing publications Anthony Atala has written about Urinary Bladder Neoplasms.
Anthony Atala
Connection Strength
10.576
Urinary Bladder Neoplasms
  1. Atala A. Re: Recurrent Activating Mutations of PPAR? Associated with Luminal Bladder Tumors. J Urol. 2019 11; 202(5):869.
    View in: PubMed
    Score: 0.594
  2. Atala A. Re: Mouse and Human Urothelial Cancer Organoids: A Tool for Bladder Cancer Research. J Urol. 2019 10; 202(4):664.
    View in: PubMed
    Score: 0.590
  3. Atala A. Re: LNMAT1 Promotes Lymphatic Metastasis of Bladder Cancer via CCL2 Dependent Macrophage Recruitment. J Urol. 2019 04; 201(4):669.
    View in: PubMed
    Score: 0.573
  4. Vasyutin I, Zerihun L, Ivan C, Atala A. Bladder Organoids and Spheroids: Potential Tools for Normal and Diseased Tissue Modelling. Anticancer Res. 2019 Mar; 39(3):1105-1118.
    View in: PubMed
    Score: 0.569
  5. Atala A. Re: Identification of MicroR-106b as a Prognostic Biomarker of p53-Like Bladder Cancers by ActMiR. J Urol. 2019 02; 201(2):231.
    View in: PubMed
    Score: 0.566
  6. Atala A. Re: An FGFR3/MYC Positive Feedback Loop Provides New Opportunities for Targeted Therapies in Bladder Cancers. J Urol. 2018 11; 200(5):947-948.
    View in: PubMed
    Score: 0.547
  7. Atala A. Re: Evasion of Immunosurveillance by Genomic Alterations of PPAR?/RXRa in Bladder Cancer. J Urol. 2018 05; 199(5):1115-1116.
    View in: PubMed
    Score: 0.530
  8. Atala A. Re: Profiling of Long Non-Coding RNAs Identifies LINC00958 and LINC01296 as Candidate Oncogenes in Bladder Cancer. J Urol. 2017 11; 198(5):983-985.
    View in: PubMed
    Score: 0.511
  9. Atala A. Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2. J Urol. 2017 11; 198(5):984-985.
    View in: PubMed
    Score: 0.511
  10. Atala A. Re: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. J Urol. 2017 11; 198(5):985.
    View in: PubMed
    Score: 0.511
  11. Atala A. Re: Claudin-Low Bladder Tumors are Immune Infiltrated and Actively Immune Suppressed. J Urol. 2017 05; 197(5):1220.
    View in: PubMed
    Score: 0.494
  12. Atala A. Re: Regulation of UHRF1 by Dual-Strand Tumor-Suppressor MicroRNA-145 (miR-145-5p and miR-145-3p): Inhibition of Bladder Cancer Cell Aggressiveness. J Urol. 2016 10; 196(4):1314.
    View in: PubMed
    Score: 0.475
  13. Atala A. Re: Mutations in TERT Promoter and FGFR3 and Telomere Length in Bladder Cancer. J Urol. 2016 04; 195(4 Pt 1):1168-9.
    View in: PubMed
    Score: 0.459
  14. Atala A. Re: Loss of Expression of the Tumour Suppressor Gene AIMP3 Predicts Survival following Radiotherapy in Muscle-Invasive Bladder Cancer. J Urol. 2015 Oct; 194(4):1162-3.
    View in: PubMed
    Score: 0.442
  15. Atala A. Re: TERT Promoter Mutations and Telomerase Reactivation in Urothelial Cancer. J Urol. 2015 Sep; 194(3):848.
    View in: PubMed
    Score: 0.440
  16. Atala A. Re: Mutations in 3'-long terminal repeat of HERV-W family in chromosome 7 upregulate syncytin-1 expression in urothelial cell carcinoma of the bladder through interacting with c-Myb. J Urol. 2015 Mar; 193(3):1061.
    View in: PubMed
    Score: 0.425
  17. Atala A. Re: Dietary sources of N-nitroso compounds and bladder cancer risk: findings from the Los Angeles Bladder Cancer Study. J Urol. 2014 Aug; 192(2):614-5.
    View in: PubMed
    Score: 0.408
  18. Atala A. Re: Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. J Urol. 2013 Dec; 190(6):2306.
    View in: PubMed
    Score: 0.389
  19. Atala A. Re: Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer. J Urol. 2013 Oct; 190(4):1437.
    View in: PubMed
    Score: 0.384
  20. Atala A. Re: PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. J Urol. 2013 Sep; 190(3):1131.
    View in: PubMed
    Score: 0.383
  21. Atala A. Re: NMR-based metabolomics study of canine bladder cancer. J Urol. 2013 Aug; 190(2):808.
    View in: PubMed
    Score: 0.380
  22. Atala A. Re: Mg(II)-Catechin Nanoparticles Delivering siRNA Targeting EIF5A2 Inhibit Bladder Cancer Cell Growth In Vitro and In Vivo. J Urol. 2017 08; 198(2):258-259.
    View in: PubMed
    Score: 0.126
  23. Atala A. Re: Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs and circRNAs with Associated Co-Expression and ceRNA Networks in Bladder Carcinoma. J Urol. 2017 01; 197(1):51-52.
    View in: PubMed
    Score: 0.121
  24. Atala A. What's new in urology. J Am Coll Surg. 2004 Sep; 199(3):446-61.
    View in: PubMed
    Score: 0.052
  25. Doherty SC, McKeown SR, McKelvey-Martin V, Downes CS, Atala A, Yoo JJ, Simpson DA, Kaufmann WK. Cell cycle checkpoint function in bladder cancer. J Natl Cancer Inst. 2003 Dec 17; 95(24):1859-68.
    View in: PubMed
    Score: 0.050
  26. Godbey WT, Atala A. Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery. Gene Ther. 2003 Aug; 10(17):1519-27.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.